The present invention provides a class of isoindolone-imide ring-1,3-dione-2-ene compounds, a preparation method, pharmaceutical composition and use thereof. Specifically, the present invention provides a class of compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by the formula (II); L is absent or is a divalent, trivalent or tetravalent linking group; and X is a group represented by the formula (III). Definitions of the other groups are as described in the specification. The compounds of formula (I) are a class of autophagy modulators, particularly mammalian ATG8 homolog modulators.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present invention relates to a compound used as an autophagy regulator, and a preparation method therefor and uses thereof. Particularly, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is an autophagy regulator and particularly, a mammalian ATG8 homologue regulator.
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/205 - Radicals derived from carbonic acid
C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
C07C 49/563 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing six-membered aromatic rings
C07C 49/567 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing halogen
C07C 49/573 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
C07C 49/577 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing ether groups, groups, groups, or groups
3.
METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE
Provided is a method for covalently modifying a mammalian ATG8 homologue, comprising providing a compound SM-LG, wherein the compound SM-LG comprises a part SM- capable of regulating the mammalian ATG8 homologue and a leaving part -LG. The compound SM-LG reacts with the mammalian ATG8 homologue to produce a mammalian ATG8 homologue covalent complex. Also provided are a mammalian ATG8 homologue covalent complex obtained by the method and a use thereof.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
4.
USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND
A use of an aminomethylenecyclohexane-1,3-dione compound. In particular, the present invention relates to a use of a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with other drug in preparing a drug for regulating or treating a disease related to autophagy, especially targeting a mammalian ATG8 homologue.
patents